TrialNature medicine2021

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.

Evdoxia Kyriazopoulou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.